JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $78

Benzinga Newsdesk www.benzinga.com Positive 62.8%

Neg 0% Neu 0% Pos 62.8%

JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from $70 to $78.